Profile data is unavailable for this security.
About the company
CHINA RESOURCES PHARMACEUTICAL GROUP LIMITED is a Hongkong-based investment holding company. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The Company mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
- Revenue in HKD (TTM)262.87bn
- Net income in HKD4.14bn
- Incorporated2007
- Employees72.99k
- LocationChina Resources Pharmaceutical Group LtdRoom 4104-05, 41F,China Resources BuldngNo. 26, Harbour Road, Wan Chai Hong KongHKG
- Phone+852 25938991
- Fax+852 25938992
- Websitehttps://www.crpharm.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Traditional Chinese Med Hldg CoLtd | 19.47bn | 1.38bn | 18.48bn | 17.30k | 13.39 | 0.813 | 6.88 | 0.9494 | 0.2742 | 0.2742 | 3.87 | 4.51 | 0.4985 | 1.47 | 2.16 | 1,125,090.00 | 3.84 | 4.60 | 5.85 | 7.07 | 51.18 | 57.07 | 7.70 | 9.77 | 1.48 | 9.83 | 0.1773 | 17.35 | 26.69 | 9.99 | 68.11 | -2.24 | -12.75 | -- |
| WuXi XDC Cayman Inc | 2.28bn | 304.59m | 19.10bn | 1.18k | 57.26 | 3.26 | 51.88 | 8.37 | 0.2784 | 0.2784 | 2.12 | 4.89 | -- | -- | -- | 1,936,789.00 | -- | -- | -- | -- | 26.35 | -- | 13.35 | -- | 4.03 | -- | 0.0005 | -- | 114.44 | -- | 82.07 | -- | -- | -- |
| HUTCHMED (China) Ltd | 6.54bn | 787.06m | 23.74bn | 1.99k | 30.37 | 4.16 | 27.82 | 3.63 | 0.8973 | 0.8973 | 7.61 | 6.55 | 0.7258 | 7.19 | 7.69 | 3,292,013.00 | 8.76 | -14.35 | 13.36 | -20.43 | 54.12 | 36.57 | 12.06 | -31.44 | 2.60 | -- | 0.1038 | -- | 96.52 | 31.38 | 127.93 | -- | 38.65 | -- |
| China Resources Pharmaceutical Group Ltd | 262.87bn | 4.14bn | 35.87bn | 72.99k | 8.66 | 0.7266 | 3.05 | 0.1365 | 0.659 | 0.659 | 41.84 | 7.86 | 1.06 | 7.06 | 3.84 | 3,601,697.00 | 3.36 | 3.02 | 12.72 | 11.35 | 15.67 | 15.72 | 3.18 | 2.87 | 1.09 | 8.70 | 0.412 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Sino Biopharmaceutical Ltd | 28.14bn | 1.98bn | 51.30bn | 25.81k | 25.51 | 1.53 | 8.49 | 1.82 | 0.107 | 0.1352 | 1.52 | 1.78 | 0.4104 | 2.31 | 5.73 | 1,090,628.00 | 7.23 | 13.11 | 13.37 | 21.74 | 80.95 | 80.37 | 17.61 | 27.47 | 0.9649 | 11.83 | 0.2479 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2023 | 86.98m | 1.39% |
| The Vanguard Group, Inc.as of 06 Jun 2024 | 65.86m | 1.05% |
| BC Investment Management Corp.as of 31 Mar 2023 | 43.25m | 0.69% |
| Dimensional Fund Advisors LPas of 06 Jun 2024 | 35.23m | 0.56% |
| BlackRock Fund Advisorsas of 06 Jun 2024 | 28.04m | 0.45% |
| The Caisse de d�p�t et placement du Qu�becas of 31 Dec 2023 | 21.82m | 0.35% |
| BlackRock Advisors (UK) Ltd.as of 06 Jun 2024 | 16.77m | 0.27% |
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 15.49m | 0.25% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 14.69m | 0.23% |
| HSBC Global Asset Management (UK) Ltd.as of 06 Jun 2024 | 13.95m | 0.22% |
